In the last trading session, 3.19 million shares of the TG Therapeutics Inc (NASDAQ:TGTX) were traded, and its beta was 2.19. Most recently the company’s share price was $29.61, and it changed around $0.07 or 0.24% from the last close, which brings the market valuation of the company to $4.41B. TGTX currently trades at a discount to its 52-week high of $36.50, offering almost -23.27% off that amount. The share price’s 52-week low was $10.98, which indicates that the current value has risen by an impressive 62.92% since then. We note from TG Therapeutics Inc’s average daily trading volume that its 10-day average is 5.61 million shares, with the 3-month average coming to 3.84 million.
TG Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 1 recommended TGTX as a Hold, whereas 6 deemed it a Buy, and 1 rated it as Underweight. TG Therapeutics Inc is expected to report earnings per share of 0.1 for the current quarter.
TG Therapeutics Inc (NASDAQ:TGTX) trade information
Instantly TGTX has showed a green trend with a performance of 0.24% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 36.50 on recent trading dayincreased the stock’s daily price by 18.88%. The company’s shares are currently up 73.36% year-to-date, but still down -3.68% over the last five days. On the other hand, TG Therapeutics Inc (NASDAQ:TGTX) is 27.03% up in the 30-day period. We can see from the shorts that 32.0 million shares have been sold at a short interest cover period of 13.37 day(s).
The consensus price target as assigned by Wall Street analysts is $23, which translates to bulls needing to decrease their stock price by -28.74% from its current value. Analyst projections state that TGTX is forecast to be at a low of $16 and a high of $55.
TG Therapeutics Inc (TGTX) estimates and forecasts
TG Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 79.67 percent over the past six months and at a 88.89% annual growth rate that is well above the industry average of 11.40%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 197.48% in revenue this quarter, and will report an increase of 292.86% in the next quarter. The year-over-year growth rate is expected to be 40.94%, up from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of 98.8M in revenue for the current quarter. 4 analysts expect TG Therapeutics Inc to make 110.84M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 43.97M and 63.47M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 124.69%. Forecasts for the next quarter put sales growth at 74.62%.
TGTX Dividends
TG Therapeutics Inc’s next quarterly earnings report is expected to be released in December.
TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 9.50% of TG Therapeutics Inc shares, and 66.33% of them are in the hands of institutional investors. The stock currently has a share float of 73.29%. TG Therapeutics Inc stock is held by 391.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 9.3645% of the shares, which is about 13.69 million shares worth $243.58 million.
BLACKROCK INC., with 7.7891% or 11.39 million shares worth $202.6 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
